Well I've been wrong on a couple of things.
I was wrong to suggest that the BLA resubmission had a 50% chance of success
But I was right that they would finally have to do another proper clinical trial for aGVHD, and that resubmitting the BLA wouldn't be a satisfactory milestone to unlock the additional Oaktree Loan.
I was right that Oaktree wouldn't extend the loan agreement.
I was right that Novartis was going to walk away from the collaboration for Covid ARDS research.
I was right that apart from the claimed success in the unsatisfactory single arm open label trial for aGVHD, every Mesoblast trial has failed to achieve the primary endpoint.
I was right that Mesoblast has effectively run out of funds, and will have difficulty finding another sucker.
banter and General Discussion, page-7717
-
- There are more pages in this discussion • 2,408 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |